New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking prowess.
The Tema Cardiovascular and Metabolic ETF, HRTS which launched Tuesday, seeks to invest in companies involved in the fight against diabetes, obesity and cardiovascular diseases. Novo Nordisk A/S DK:NOVO.B, Eli Lilly & Co. LLY, Amgen Inc. AMGN and Vertex Pharmaceuticals Inc. VRTX were among the equity fund’s top holdings…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here